Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device

P.N. Richard Dekhuijzen, Maria Batsiou, Leif Bjermer, Sinthia Bosnic-Anticevich, Henry Chrystyn, Alberto Papi, Roberto Rodriguez-Roisin, Monica Fletcher, Lucy Wood, Alessandra Cifra, Joan B Soriano, David B. Price

Research output: Contribution to journalArticle

12 Citations (Scopus)
5 Downloads (Pure)

Abstract

Background and aims

Little information is available on real-life occurrence of oral thrush in COPD patients treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and delivery device.

Methods

We conducted a historical, observational, matched cohort study (one baseline year before and one outcome year after initiation of therapy) using data from the UK Optimum Patient Care Research Database. We assessed oral thrush incidence in patients initiating long-acting bronchodilators or FDC ICS/LABA therapy. We then compared different combination therapies (budesonide/formoterol fumarate dihydrate [BUD/FOR] and fluticasone propionate/salmeterol xinafoate [FP/SAL]) and devices (DPI and pMDI).

Results

Patients prescribed FDC ICS/LABA had significantly greater odds of experiencing oral thrush than those prescribed long-acting bronchodilators alone (adjusted OR 2.18 [95% CI 1.84–2.59]). Significantly fewer patients prescribed BUD/FOR DPI developed oral thrush compared with FP/SAL DPI (OR 0.77 [0.63–0.94]) when allowing for differences in prescribed doses between the drugs. A significantly smaller proportion of patients developed oral thrush in the FP/SAL pMDI arm than in the FP/SAL DPI arm (OR 0.67 [0.55–0.82]). Additionally, in the FP/SAL cohort (both DPI and pMDI), increased risk of oral thrush was significantly associated with high ICS daily dose (OR 1.97 [1.22–3.17] vs low daily dose).

Conclusions

ICS use increases oral thrush incidence in COPD and this effect is dose-dependent for FP/SAL therapies. Of the therapies assessed, FP/SAL pMDI and BUD/FOR DPI may be more protective against oral thrush.
Original languageEnglish
Pages (from-to)54-63
Number of pages10
JournalRespiratory Medicine
Volume120
Early online date22 Sep 2016
DOIs
Publication statusPublished - Nov 2016

Keywords

  • oral candidiasis
  • chronic obstructive pulmonary disease
  • inhaled corticosteroid
  • spacer
  • dry powder inhaler
  • pressurised metered-dose inhaler

Fingerprint Dive into the research topics of 'Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device'. Together they form a unique fingerprint.

  • Cite this

    Dekhuijzen, P. N. R., Batsiou, M., Bjermer, L., Bosnic-Anticevich, S., Chrystyn, H., Papi, A., Rodriguez-Roisin, R., Fletcher, M., Wood, L., Cifra, A., Soriano, J. B., & Price, D. B. (2016). Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: Effect of drug, dose, and device. Respiratory Medicine, 120, 54-63. https://doi.org/10.1016/j.rmed.2016.09.015